{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:36:43Z","timestamp":1787960203398,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.2215\/cjn.06370615","type":"journal-article","created":{"date-parts":[[2015,11,27]],"date-time":"2015-11-27T22:08:30Z","timestamp":1448662110000},"page":"539-546","source":"Crossref","is-referenced-by-count":24,"title":["Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis"],"prefix":"10.2215","volume":"11","author":[{"given":"Patrick S.","family":"Parfrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman B.","family":"Dr\u00fceke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M.","family":"London","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20230601","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-23-20230601","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2215\/CJN.01930408","article-title":"Accelerated atherosclerotic calcification and Monckeberg\u2019s sclerosis: A continuum of advanced vascular pathology in chronic kidney disease","volume":"3","author":"McCullough","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R4-23-20230601","doi-asserted-by":"crossref","first-page":"e001363","DOI":"10.1161\/JAHA.114.001363","article-title":"Effects of cinacalcet on atherosclerotic and non atherosclerotic cardiovascular events in patients receiving hemodialysis. The Evaluation of Cinacalcet HCC Therapy to lower CardioVascular Events (EVOLVE) Trial","volume":"17","author":"Wheeler","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"R5-23-20230601","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2215\/CJN.02120508","article-title":"Media calcification and intima calcification are distinct entities in chronic kidney disease","volume":"3","author":"Amann","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-23-20230601","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ahj.2014.11.003","article-title":"Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium","volume":"169","author":"Seltzer","year":"2015","journal-title":"Am Heart J"},{"key":"R7-23-20230601","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jacc.2014.01.020","article-title":"Proposal for a functional classification system of heart failure in patients with end-stage renal disease: Proceedings of the acute dialysis quality initiative (ADQI) XI workgroup","volume":"63","author":"Chawla","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R8-23-20230601","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ki.1995.132","article-title":"Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors","volume":"47","author":"Harnett","year":"1995","journal-title":"Kidney Int"},{"key":"R9-23-20230601","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1468-6708-3-10","article-title":"Validation of heart failure events in the antihypertensive and lipid lowering treatment to prevent heart attack Trial (ALL HAT) participants assigned to doxazosin and chlorthalidone","volume":"3","author":"Piller","year":"2002","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"R10-23-20230601","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1067\/mhj.2002.120145","article-title":"Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb\/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial","volume":"143","author":"Mahaffey","year":"2002","journal-title":"Am Heart J"},{"key":"R11-23-20230601","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/CVM-2-4-187","article-title":"Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: Review of the PURSUIT study","volume":"2","author":"Mahaffey","year":"2001","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"R12-23-20230601","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1210\/jc.2013-2975","article-title":"The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: The EVOLVE trial","volume":"98","author":"Parfrey","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R13-23-20230601","doi-asserted-by":"crossref","first-page":"e36677","DOI":"10.1371\/journal.pone.0036677","article-title":"Assessment and implication of prognostic balance in randomized controlled trials with a binary outcome\u2014a simulation study","volume":"7","author":"Chu","year":"2012","journal-title":"PLOS One"},{"key":"R14-23-20230601","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimide in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"R15-23-20230601","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"R16-23-20230601","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: Explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Ann Intern Med"},{"key":"R17-23-20230601","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jclinepi.2009.06.002","article-title":"A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: A review of trials published in leading medical journals","volume":"63","author":"Austin","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"R18-23-20230601","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.annepidem.2005.09.007","article-title":"Randomized controlled trials with time-to-event outcomes: How much does prespecified covariate adjustment increase power?","volume":"16","author":"Hern\u00e1ndez","year":"2006","journal-title":"Ann Epidemiol"},{"key":"R19-23-20230601","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial","volume":"10","author":"Parfrey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R20-23-20230601","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2288-5-26","article-title":"The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials\u2014a secondary analysis","volume":"5","author":"Walach","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"R21-23-20230601","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ndt\/gfv068","article-title":"Lag-censoring analysis: Lights and shades","volume":"30","author":"Tripepi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R22-23-20230601","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pst.1680","article-title":"Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial","volume":"14","author":"Kubo","year":"2015","journal-title":"Pharm Stat"},{"key":"R23-23-20230601","doi-asserted-by":"crossref","first-page":"e1553","DOI":"10.1136\/bmj.e1553","article-title":"Credibility of claims of subgroup effects in randomised controlled trials: systematic review","volume":"344","author":"Sun","year":"2012","journal-title":"BMJ"},{"key":"R24-23-20230601","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2215\/CJN.10221014","article-title":"The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE trial","volume":"10","author":"Floege","year":"2015","journal-title":"Clin J Am Soc Nephol"},{"key":"R25-23-20230601","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2215\/CJN.03350315","article-title":"Evolving calciphylaxis\u2014what randomized, controlled trials can contribute to the capture of rare diseases","volume":"10","author":"Ketteler","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-23-20230601","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2215\/CJN.11541114","article-title":"Cross-disciplinary biomarkers research: lessons learned by the CKD Biomarkers Consortium","volume":"10","author":"Hsu","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"R27-23-20230601","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"R28-23-20230601","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"R29-23-20230601","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"R30-23-20230601","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R33-23-20230601","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201603000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:58Z","timestamp":1786369558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201603000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.06370615","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}